

# REPLACEMENT OF GLYCOPROTEIN B GENE IN THE HERPES SIMPLEX VIRUS TYPE 1 STRAIN ANGpath DNA BY THAT ORIGINATING FROM NONPATHOGENIC STRAIN KOS REDUCES THE PATHOGENICITY OF RECOMBINANT VIRUS

M.KOŠTÁL<sup>1</sup>, I. BAČÍK<sup>1</sup>, J. RAJČÁNI<sup>1\*</sup>, H.C. KAERNER<sup>2</sup>

<sup>1</sup>Institute of Virology, Slovak Academy of Sciences, Dúbravská cesta 9, 842 46 Bratislava, Slovak Republic;

<sup>2</sup>Institute of Virus Research, German Cancer Research Center, 6900 Heidelberg, Germany

*Received July 23, 1993; revised November 19, 1993*

**Summary.** – Herpes simplex virus type-1 (HSV-1) strain ANGpath and its recombinants, in which the 8.1 kbp *Bam*HI G restriction fragment (0.345 – 0.399) containing the glycoprotein B (gB<sup>path</sup>) gene (UL27) or its subfragments—coding either for cytoplasmic or surface domains of gB—had been replaced with the corresponding fragments from nonpathogenic KOS virus DNA (gB<sup>KOS</sup>), were tested for their pathogenicity for DBA/2 mice and rabbits. The recombinant ANGpath/B6<sup>KOS</sup> prepared by transferring the 2.7 kbp *Sst*I-*Sst*I subfragment (0.351 – 0.368) of the *Bam*HI G<sup>KOS</sup> fragment still had the original sequence of ANGpath DNA coding for the syn<sup>3</sup> marker in the cytoplasmic domain of gB and was pathogenic for mice as well as for rabbits. Virological and immunohistological studies in DBA/2 mice infected with the latter pathogenic recombinant and with ANGpath showed the presence of infectious virus and viral antigen at inoculation site (epidermis, subcutaneous connective tissue and striated muscle in the area of right lip), in homolateral trigeminal nerve and ganglion, brain stem, midbrain, thalamic and hypothalamic nuclei. In contrast, nonpathogenic recombinants ANGpath/syn<sup>+</sup>B6<sup>KOS</sup> (prepared by transferring the whole *Bam*HI G<sup>KOS</sup> fragment) and ANGpath/syn<sup>+</sup>KOS (prepared by transferring the 0.8 kbp *Bam*HI-*Sst*I subfragment of the *Bam*HI G<sup>KOS</sup> fragment) showed limited haematogenous and neural spread, but no evidence of replication in CNS; thus, their behaviour resembled that of the wild type strain KOS. The recombinant ANGpath/syn<sup>+</sup>KOS, which was not pathogenic for mice, still remained pathogenic for rabbits, a phenomenon indicating the presence of an additional locus in the gB molecule participating on virulence. Sequencing the 1478 bp *Sst*I-*Sst*I subfragment of the *Bam*HI G<sup>path</sup> fragment (nt 53,348 – 54,826 of UL segment) showed the presence of at least 3 mutations as compared to the KOS sequence, from which the change of cytosine to thymine at nt 54,251 altered the codon for arginine to that for histidine (amino acid 515) in the gB polypeptide chain.

**Key words:** herpes simplex virus type 1; glycoprotein B; pathogenicity; recombinants; mutation

## Introduction

The gB of HSV-1 is essential for its infectivity by inducing membrane fusion and facilitating penetration (Haffey and Spear, 1980; Spear, 1985). The gB polypeptide chain has a N-terminal 29 amino acid (aa) long cleavable signal sequence, a 696 aa long hydrophilic surface domain with 6 potential glycosylation sites, a 109 aa long C-terminal domain projecting into cytoplasm and a 69 aa hydrophobic

transmembrane domain (Pellet *et al.*, 1985). A single aa change in the cytoplasmic domain at position 857 causes extensive fusion in tsB5 mutant-infected Vero cells (Bzik *et al.*, 1984). This locus called syn<sup>3</sup> (Ruyechan *et al.*, 1979) was mapped to coordinates 0.345 – 0.355 (deLuca *et al.*, 1982). The suggested role of gB in HSV envelopment was not confirmed (Cai *et al.*, 1987). Monoclonal antibodies (MoAbs) distinguished up to 18 epitopes clustered in 4 antigenic domains (Pereira *et al.*, 1989). The gB gene maps to the *Bam*HI G fragment (0.345 – 0.399) (Pereira *et al.*, 1982), more precisely to UL 27 (nt 53,083 – 55,794 (McGeoch *et al.*, 1988).

\*Corresponding author

When *Bam*HI G fragment from KOS DNA (*Bam*HI G<sup>KOS</sup>) was cotransfected with the ANGpath DNA into BHK cells, the recombinant selected was syn<sup>+</sup> (nonsyn) and positive for staining by MoAbs B6 which detects a specific epitope for gB<sup>KOS</sup> (Weise *et al.*, 1987). The B6 locus maps in the *Sst*I-*Sst*I (2.7 kb) subfragment of the *Bam*HI G fragment upstream from the *Sa*I site (Fig. 1). Additional recombinants were prepared after cotransfection of ANGpath DNA with smaller *Bam*HI G<sup>KOS</sup> subfragments such as *Bam*HI-*Sst*I<sup>KOS</sup> (0.8 kbp) and *Sst*I-*Sst*I<sup>KOS</sup> (2.7 kbp), and selected according to the syn<sup>+</sup> (no giant cells) and/or the B6<sup>+</sup> phenotypes. Strain ANGpath virus derived from strain ANG (Kaerner *et al.*, 1983) is pathogenic for mice after peripheral inoculation (Kümel *et al.*, 1986). While ANG as well as KOS can be transported to the regional sensory ganglion by axonal route to establish latency (Schröder and Kümel, 1986; Rajčáni *et al.*, 1990a), only ANGpath would spread beyond the first neuron and reach CNS. Neural spread of ANGpath in the mouse model is more complex; it can be traced by immunofluorescence and peroxidase-anti-peroxidase (PAP) staining because of active replication and antigen production in Schwann cells of peripheral nerves and in glial cells at the entry site of cerebrospinal nerves (Rajčáni *et al.*, 1990a). Here we present evidence that recombination of KOS DNA fragment(s) coding for gB into ANGpath DNA reduces the ability of ANGpath to spread from the inoculation site both by haematogenous and neural routes. The latter remains restricted to silent axonal spread followed with establishment of latency in the absence of virus replication in CNS during the acute postinfection period.

## Materials and Methods

**Viruses.** Strain ANGpath (Kaerner *et al.*, 1983), wild type strain KOS (Holland *et al.*, 1983) and the recombinants (Table 1) were obtained from the German Cancer Research Center (DKFZ),

Heidelberg. The recombinants were prepared as previously described (Weise *et al.*, 1987; Lange-Bay, 1990). Briefly, BHK-21 cells were cotransfected with either the *Bam*HI G fragment from KOS DNA or its subfragments *Bam*HI-*Sst*I (0.345 – 0.351) or *Sst*I-*Sst*I (0.351 – 0.368) and with ANGpath DNA by the calcium phosphate precipitation method (Graham *et al.*, 1973). The "black plaque assay" before selection of gB<sup>KOS</sup> B6 marker was made according to Holland *et al.* (1983) using the anti-B6 MoAb (kindly provided by Dr. J. C. Glorioso, University of Pittsburgh, PA, USA), anti-mouse IgG/Px-labelled conjugate (Dianova, Hamburg, Germany) and 4-chloro-1-naphthol as substrate.

**Animals.** DBA/2 mice were simultaneously inoculated into the right lip subcutaneously (sc) and into the right cornea with a total virus dose of  $2 \times 10^6$  PFU. The lethality was registered and autopsies were performed on days 3, 6 and 9 post infection (p.i.). Following organs were sampled for virus titration and morphological examination: right lip, both trigeminal ganglia, brain stem, cerebellum, midbrain, brain hemispheres, spinal cord with spinal ganglia, adrenal glands with kidneys and retroperitoneal vegetative ganglia, liver and spleen. Albino rabbits (3 000 g) were inoculated with  $2 \times 10^6$  PFU of virus into the right scarified cornea in a volume of 50  $\mu$ l. The animals were observed for 2 – 4 months. At autopsy, both trigeminal ganglia, right brain stem (at the entrance of trigeminal nerve root) and right cornea were removed under sterile conditions, minced and cultured for 10 days as described below.

**Virus infectivity titrations** were made in Vero cells grown on 24-well microplates (Nunc) in Eagle's Basal Medium supplemented with 10% foetal calf serum (FCS), 10 mmol/l HEPES buffer, 2 mmol/l L-glutamine and antibiotics. Plaques were counted within 2, 3 and 4 days of incubation at 37 °C in 5% CO<sub>2</sub> atmosphere; titers were expressed in PFU either per total tissue sample used to prepare the 10% suspension (for details see Rajčáni *et al.*, 1990a) or per 0.1 g organ weight.

**Morphological examinations.** For indirect immunofluorescence (IF) staining tissues were quickly frozen in liquid nitrogen, cut in cryostat and fixed in acetone. The sections were stained with rabbit anti-HSV-1 (strain McIntyre) hyperimmune globulin (Da-

**Table 1. Recombinants constructed by replacement of *Bam*HI G fragment or its subfragments in ANGpath DNA by KOS DNA fragments**

Designation	Recipient virus	Fragment transferred	Phenotype	Pathogenicity	Axonal spread
KOS <sup>a</sup>	KOS	none	syn <sup>+</sup> , B6 <sup>+</sup>	low	frequent
ANGpath	ANGpath	none	syn, B6 <sup>-</sup>	high	frequent
ANGpath/syn <sup>+</sup> B6 <sup>KOS</sup>	ANGpath	<i>Bam</i> HI G <sup>KOS</sup> (8.1 kbp, 0.345 – 0.399)	syn <sup>+</sup> , B6 <sup>+</sup>	low	present
ANGpath/syn <sup>+</sup> KOS	ANGpath	<i>Bam</i> HI- <i>Sst</i> I <sup>KOS</sup> (0.8 kbp, 0.345 – 0.351)	syn <sup>+</sup> , B6 <sup>-</sup>	low	present
ANGpath/B6 <sup>KOS</sup>	ANGpath	<i>Sst</i> I- <i>Sst</i> I <sup>KOS</sup> (2.7 kbp, 0.351 – 0.368)	syn, B6 <sup>+</sup>	high	frequent

<sup>a</sup>Wild type strain; syn = giant cell morphology; syn<sup>+</sup> = nonsyncytial morphology




Fig. 1

**Location of BamHI fragment and its subfragments in HSV-1 DNA**

A: genomic DNA. Map coordinates 0–1.0, segments UL and US, inverted repeats a, b, c, and a', b', c'. B: BamHI G fragment (8.1 kbp). Restriction sites and their map coordinates. gB gene (box), the sequenced *SstI*-*SalI* subfragment (hatched area), direction of transcription of gB gene (horizontal arrow). C: the sequenced *SstI*-*SalI* subfragment (nt 1–1478). Specific primers SP1 and SP2 are marked by horizontal arrows. D: gB polypeptide chain (aa 1–904). Hydrophobic transmembraneous regions (black areas), mutations M1 (aa 854) and M2 (aa 515), loci syn3 (aa 857), B6, disulfhydryl bridges for dimer formation (aa 225 and 675), E (entry site, aa 525), signal sequence (aa 1–29). For M1 see Lange-Bay (1990), for syn<sup>3</sup> Bzik *et al.* (1984) and for E de Luca *et al.* (1982).

ko) and goat anti-rabbit conjugate (GAR/FITC) as described (Rajčáni *et al.*, 1990a). The sections were counterstained with thiazine red and mounted into Tris-buffered glycerine (1 part of 0.1 mol/l Tris.HCl pH 7.5 and 9 parts of glycerine). For immunoperoxidase staining the tissues were fixed with acid formalin (73.5 % ethanol, 24.5 % glacial acetic acid, 2 % formalin) when removed from animals perfused through the left ventricle using the same fixative in deep Methophane anesthesia. After embedding into paraffin the sections were deparaffinized in xylol and alcohol series, and rinsed in PBS. The endogenous peroxidase was blocked by incubation with 3% H<sub>2</sub>O<sub>2</sub>, then the sections were washed in PBS, blocked with normal swine serum and subsequently incubated with hyperimmune rabbit serum at 37 °C for 40 mins. Following 3 washes in PBS the sections were treated with the bridging antibody (swine anti-rabbit IgG, Dako) and then with the

rabbit PAP complex (Dako) according to manufacturer's instructions. After final washing the sections were rinsed in 0.1 mol/l acetate pH 5.2 and incubated for 30 mins with aminoethylcarbazol (Sigma) in acetate buffer as described (Culling *et al.*, 1985). The sections were counterstained with Mayer's haemalaun and mounted into glyceringelatin.

**Latency reactivation.** Latent HSV-1 infection was tested in Gasserian ganglia of DBA/2 mice after lip/cornea inoculation at 31–46 days p.i. and in rabbits after corneal inoculation at 40–60 days p.i. as previously described (Rajčáni *et al.*, 1990b). The minced ganglion fragments were cultured in plastic dishes for 10 days in medium RPMI-1640 supplemented with 10% FCS, 10 mmol/l Hepes, 2 mmol/l L-glutamine and 5 µmol/l 5-azacytidine (Serva) as inducer. Medium was changed on days 3 and 7 (inducer-free) in culture. The medium samples from days 7 and 10 in culture as well as the collected ganglion fragments were tested for virus presence in Vero cells grown on 24-well microplates.

**DNA sequencing.** The 1.5 kbp *SstI* (*SacI*)-*SalI* subfragment of the BamHI G<sup>path</sup> fragment (Fig. 1) from nt 53,348 to 54,826 of the UL segment in strain 17 DNA (McGeoch, 1988) was cleaved with *FspI* (cleavage site at nt 54,033–54,038). The resulting *SstI*-*FspI* (684 nt long) and *FspI*-*SalI* (794 nt long) subfragments were inserted into *SacI*-*SmaI* and/or *SmaI*-*SalI* polylinker sites of pUC19. The plasmid DNA was first cleaved with *SmaI* to create blunt ends and then digested either with *SstI* or with *SalI*. Then the *SstI*-*FspI* and the *FspI*-*SalI* subfragments were ligated at corresponding ends of the vector and transfected into *E. coli* WK6 cells. The cloned vector DNAs containing either of inserted subfragments were purified by CsCl-gradient centrifugation and sequenced by the chain-termination dideoxynucleoside triphosphosphate method (Sanger *et al.*, 1977) using the T7-Sequencing kit (Pharmacia LKB Biotechnology). Specific downstream (5'-GTGGATGACCGTGTCTGA-3', nt 275–292) and upstream (5'-GACTGCATCGGCAAGGA-3', nt 1217–1201) primers were synthesized taking advantage of the published strain 17 sequence and used downstream from the *SstI* site or upstream from *SalI* site (Fig. 1). The universal sequencing primers were used in downstream direction from *SstI* and/or *FspI* insertion sites and in upstream direction from *SalI* and/or *FspI* sites. The labelling reaction was performed with [α-<sup>35</sup>S]dATP and 3 units of T7 DNA polymerase (5 mins incubation at 37 °C). The denatured reaction mixture was electrophoresed on 6% acrylamide gel containing 8 mol/l urea in TBE buffer at 55 °C and 50 V/cm using the 2010 Macrophor apparatus (Pharmacia LKB Biotechnology). By the end of the run, the gel was washed in 10% acetic acid, air dried and exposed to Kodak X-AR film.

**Results***Virus distribution in mice and rabbits during acute and latent infection*

Following combined lip and corneal inoculations, the strains KOS, ANGpath as well as all the 3 recombinants replicated at the inoculation site. ANGpath strain and the

pathogenic recombinant ANGpath/B6<sup>KOS</sup> spread to CNS and visceral organs (Table 2). Despite a limited replication

**Table 2. Distribution of infectious virus in mice infected with ANGpath strain and pathogenic recombinant ANGpath/B6**

Organ (tissue)	ANGpath			ANGpath/B6 <sup>KOS</sup>		
	Virus titers at days p.i.					
	3	6	9 <sup>a</sup>	3	6	9
Right lip	2 × 10 <sup>4</sup>	1 × 10 <sup>3</sup>	9 × 10 <sup>2</sup>	1 × 10 <sup>5</sup>	6 × 10 <sup>3</sup>	nd
RTG	1 × 10 <sup>2</sup>	1 × 10 <sup>2</sup>	2 × 10 <sup>1</sup>	1 × 10 <sup>3</sup>	1 × 10 <sup>2</sup>	nd
LTG	neg	neg	neg	neg	neg	nd
Brain stem	1 × 10 <sup>3</sup>	3 × 10 <sup>3</sup>	neg	2 × 10 <sup>1</sup>	1 × 10 <sup>3</sup>	nd
Cerebellum	neg	neg	neg	neg	1 × 10 <sup>2</sup>	nd
Midbrain	4 × 10 <sup>2</sup>	1 × 10 <sup>4</sup>	neg	neg	2 × 10 <sup>0</sup>	nd
Cortex	neg	neg	neg	neg	neg	neg
Spinal cord	neg	1 × 10 <sup>1</sup>	neg	5 × 10 <sup>1</sup>	neg	nd
SVG	neg	neg	neg	2 × 10 <sup>1</sup>	neg	nd
Adrenal gl.	neg	neg	neg	1 × 10 <sup>5</sup>	2 × 10 <sup>2</sup>	nd
Spleen	neg	neg	neg	neg	neg	neg
Lethality			Lethality			
	0/16	7/13	11/13	0/15	3/12	11/12

Inoculation dose  $2 \times 10^6$  PFU. Virus titers expressed in PFU per 0.1 g tissue (lip, different brain samples) or per whole organ sample (ganglia, spinal cord, adrenal gland, spleen). RTG – right trigeminal (Gasserian) ganglion; LTG – left trigeminal ganglion; SVG – spinal and vegetative ganglia; nd – not done; neg –  $<1 \times 10^0$ . <sup>a</sup> No virus was found in the CNS of survivor mouse.

of KOS was also found in the right trigeminal ganglion by day 6 p.i., both nonpathogenic recombinants (ANGpath/syn<sup>+</sup>B6<sup>KOS</sup> and ANGpath/syn<sup>+</sup>B6<sup>KOS</sup>) remained restricted to the inoculation site (Table 3). Lethality and distribution of ANGpath/B6<sup>KOS</sup> in DBA/2 mice closely resembled that of ANGpath indicating the presence of a dominant virulence-associated mutation in the *BamHI-SstI* subfragment of ANGpath coding for the cytoplasmic domain of gB. Nevertheless, the ANGpath/B6<sup>KOS</sup> recombinant was still pathogenic for rabbits (Table 4), indicating that lethality of ANGpath for rabbits was reduced (to 13%) only when the whole gB gene had been replaced by the KOS sequence (ANGpath/syn<sup>+</sup>B6<sup>KOS</sup>). Table 4 also shows that both nonpathogenic viruses, KOS and ANGpath/syn<sup>+</sup>B6<sup>KOS</sup>, spread by axons to the right trigeminal ganglion establishing latency in about 33% of survivors. The presence of infectious virus was also tested in the cornea and brain of rabbits which succumbed infection on days 4 – 12 p.i. In lethal cases the virus was present in brain stem, occasionally also in brain cortex, spinal cord and spleen (data not shown). Unlike to mice, no virus was isolated from adrenal glands (compare Tables 2 and 3), which indicates that neural spread was the main route of virus transmission after corneal inoculation. Latency competence as an indicator of the ability of recombinants to spread by axonal route to the regional sensory ganglion (first neuron) is documented in Table 5. The spread of the nonpathogenic recombinants ANG-

**Table 3. Distribution of infectious virus in mice infected with KOS strain and nonpathogenic recombinants ANGpath/syn<sup>+</sup>B6<sup>KOS</sup> and ANGpath/syn<sup>+</sup>B6<sup>KOS</sup>**

Organ (tissue)	KOS			ANGpath/syn <sup>+</sup> B6 <sup>KOS</sup>			ANGpath/syn <sup>+</sup> B6 <sup>KOS</sup>		
	Virus titers at days p.i.								
	3	6	9	3	6	9	3	6	9
Right lip	1 × 10 <sup>5</sup>	4 × 10 <sup>1</sup>	neg	2 × 10 <sup>4</sup>	neg	neg	3 × 10 <sup>4</sup>	5 × 10 <sup>5</sup>	neg
RTG	neg	1 × 10 <sup>1</sup>	neg	neg	neg	neg	neg	neg	neg
LTG	neg	neg	neg	neg	neg	neg	neg	neg	neg
Brain stem	neg	neg	neg	neg	neg	neg	neg	neg	neg
Cerebellum	neg	neg	neg	neg	neg	neg	neg	neg	neg
Midbrain	neg	neg	neg	neg	neg	neg	neg	neg	neg
Cortex	neg	neg	neg	neg	neg	neg	neg	neg	neg
Spinal cord	neg	neg	neg	neg	neg	neg	neg	neg	neg
SVG	neg	neg	neg	neg	neg	neg	neg	neg	neg
Adrenal gl.	neg	neg	neg	neg	neg	neg	neg	neg	neg
Spleen	neg	neg	neg	neg	neg	neg	neg	neg	neg
	Lethality			Lethality			Lethality		
	1/15	1/12	1/9	0/15	0/12	0/9	0/15	1/12	1/9

Virus titers expressed in PFU per 0.1 g lip tissue or per whole ganglion sample. For details see Table 2.

**Table 4. Lethality and latency competence of KOS strain and ANGpath/gB<sup>KOS</sup> recombinants for rabbits**


Virus	Lethality	Latency			
		RTG	LTG	RBS	RC
KOS	0/7	3/7 (42.8%)	0/7	1/7 (14.3%)	0/7
ANGpath/syn <sup>+</sup> B6 <sup>KOS</sup>	2/15 (13%)	5/13 (38.4%)	1/13 (7.6%)	2/13 (15.3%)	1/13 (7.7%)
ANG/syn <sup>+</sup> KOS	19/22 (86%)	0/3	0/3	0/13	0/13
ANGpath/B6 <sup>KOS</sup>	7/8 (87%)	0/1	0/1	0/1	0/1

For other abbreviations see Table 2.

**Table 5. Latency competence of the ANGpath recombinants for mice**

Virus	Virus dose (PFU)	Days p.i.	RTG	LTG	Brain stem
ANGpath <sup>a</sup>	1 × 10 <sup>5</sup>	30	6/8 (75%)	0.8	nd
	1 × 10 <sup>4</sup>	90	10/16 (62.5%)	0/16	nd
KOS	5 × 10 <sup>5</sup>	31	14/17 (82%)	3/17 (17.6%)	0/17
ANGpath/syn <sup>+</sup> B6 <sup>KOS</sup>	5 × 10 <sup>5</sup>	46	6/18 (33%)	0/18	2/18 (11.1%)
ANGpath/B6 <sup>KOS a</sup>	5 × 10 <sup>4</sup>	32	10/17 (59%)	0/17	0/17
ANGpath/syn <sup>+</sup> KOS	5 × 10 <sup>5</sup>	36	7/15 (47%)	0/15	0/15

<sup>a</sup>For lethality during acute infection see Table 2. For abbreviations see Table 2.

**Fig. 2**

Subcutaneous connective tissue at the site in the lip of DBA/2 mouse on day 3 p.i. with recombinant ANGpath/B6<sup>KOS</sup>. HSV antigen is present in elongated fibrocytes, mononuclear cells and endothelium cells of postcapillary venules (magn. × 200).

path/syn<sup>+</sup>B6<sup>KOS</sup> and ANGpath/syn<sup>+</sup>KOS was reduced to 33% and/or 47%, respectively. In comparison to KOS this was a significant reduction ( $p = 0.05$ ); nevertheless, both nonpathogenic recombinants clearly spread by axonal route.

#### *Morphological findings in mice during acute infection*

Immunohistological localization of viral antigen in the tissues was in accord with the virus infectivity assays described above. The pathogenic strain ANGpath and the pathogenic recombinant ANGpath/B6<sup>KOS</sup> showed clearcut positive staining at the inoculation site, within peripheral nerves, in the trigeminal ganglion, brain stem and in other parts of CNS (Table 6). In addition, there was no HSV-specific antigen in the CNS of mice infected with KOS w.t. and with the nonpathogenic recombinants ANGpath/syn<sup>+</sup>B6<sup>KOS</sup> and ANGpath/syn<sup>+</sup>KOS (Table 7). The latter recombinant showed occasional positive staining in the right trigeminal ganglion on day 3 p.i. (compare Table 3).

In mice infected with the pathogenic strain ANGpath and pathogenic recombinant ANGpath/B6<sup>KOS</sup> (i.e. those expressing syn phenotype), HSV-1 antigen was present in the following structures of inoculated lip area: epidermis, mononuclear cells and fibrocytes of subcutaneous connective tissue, endothelium cells of venules and capillaries (Fig. 2), and in the Schwann cells of nerve fibers. Extensive

**Table 6. Distribution of viral antigen in mice infected with ANGpath strain and pathogenic recombinant ANGpath/B6<sup>KOS</sup>**

Organ (tissue)	ANGpath			ANGpath/B6 <sup>KOS</sup>		
	Antigen at days p.i.					
	3	6	9 <sup>a</sup>	3	6	9
Right lip	+	+	+	+	+	+
RTG	+	+	—	+	+	+
LTG	—	—	—	—	—	—
NTNT	—	+	—	+	+	+
FR	—	+	—	—	+	+
Cerebellum	—	+	—	—	+	—
Midbrain	+	+	—	+	+	+
Hypothalamus	—	—	—	—	+	+
Thalamus	—	+	—	—	+	+
Cortex	—	—	—	—	+	—
Gyn. dentatus	—	—	—	—	—	—
Spinal cord	—	—	—	—	—	—
SVG	—	—	—	—	—	—
Adrenal gl.	—	—	—	—	—	—
Liver	—	—	—	—	—	—
Spleen	+	—	—	—	—	—

The presence of antigen was tested by IF and PAP staining. NTNT – nucleus terminalis nervi trigemini; FR – formatio reticularis; (++) – antigen present; (–) – antigen absent. For other abbreviations see Table 2.

\*No viral antigen was found in CNS of the survivor mouse.

**Table 7. Distribution of viral antigen in mice infected with KOS strain and nonpathogenic recombinants ANGpath/syn<sup>+</sup>B6<sup>KOS</sup> and ANGpath/syn<sup>+</sup>KOS**

Organ (tissue)	KOS			ANGpath/ syn <sup>+</sup> B6 <sup>KOS</sup>			ANGpath /syn <sup>+</sup> KOS		
	Antigen at days p.i.								
	3	6	9	3	6	9	3	6	9
Right lip	+	+	—	+	+	—	+	+	+
RTG	—	+	—	—	—	—	+	—	—
LTG	—	—	—	—	—	—	—	—	—
NTNT	—	—	—	—	—	—	—	—	—
FR	—	—	—	—	—	—	—	—	—
Cerebellum	—	—	—	—	—	—	—	—	—
Midbrain	—	—	—	—	—	—	—	—	—
Hypothalamus	—	—	—	—	—	—	—	—	—
Thalamus	—	—	—	—	—	—	—	—	—
Cortex	—	—	—	—	—	—	—	—	—
Gyr. dentatus	—	—	—	—	—	—	—	—	—
Spinal cord	—	—	—	—	—	—	—	—	—
SVG	—	—	—	—	—	—	—	—	—
Adrenal gl.	—	—	—	+	—	—	—	—	—
Liver	—	—	—	—	—	—	—	—	—
Spleen	—	—	—	—	—	—	—	—	—

For legend see Tables 2 and 6.

positive staining was found in the sarcoplasm of adjacent striated muscle cells with accumulation of the antigen below sarcolemma, in small nerve fibers, and in the walls of venules (Fig. 3). Sections of lips from mice infected with nonpathogenic recombinants ANGpath/syn<sup>+</sup>B6<sup>KOS</sup> and ANGpath/syn<sup>+</sup>KOS showed HSV antigen in a few mononuclear macrophages in subcutaneous connective tissue (Fig. 4) and in a few striated muscle cells. In contrast to these nonpathogenic recombinants, the pathogenic ANGpath and ANGpath/B6<sup>KOS</sup> recombinants showed abundant fluorescence in the neurons and satellite cells of right trigeminal ganglion (Fig. 5, 6), in Schwann cells of the homolateral trigeminal nerve and in CNS. Positive neurons and glial cells were seen most frequently in the brain stem, mainly in the area of nucleus terminalis nervi trigemini (Fig. 7), in the midbrain, thalamic nuclei and in the hypothalamic area. Brain cortex and cerebellum remained spared. Dissemination of the virus via bloodstream to spleen or adrenal glands occurred rarely. In the spleen viral antigen was seen mainly

in the red pulp and in the wall of sinuses within endothelium cells, reticulum cells and mononuclear leukocytes. Viral antigen was present in adrenal cortex of a mouse infected with the nonpathogenic recombinant ANGpath/syn<sup>+</sup>B6<sup>KOS</sup>.

#### *Sequencing of SstI-SalI subfragment of ANGpath DNA*

The gB (UL 27) gene spans from nt 53,079 to 55,794 of the UL segment. The *SstI*-*SalI* subfragment of ANGpath DNA corresponds to the portion of gB gene from nt 53,348 to 54,826. The 1478 nt long *SstI*-*SalI*<sup>path</sup> subfragment differed from that of KOS in 3 nucleotides. At nt 54,251 (903 in Fig. 8) cytosine was changed to thymine, which altered the codon CGC (coding for arginine in the transcribed strand of KOS DNA) to CAC (coding for histidine in ANGpath DNA). This changed aa 515 of the gB polypeptide chain. An another change was found at nt 86/87 (Fig. 8), altering the codon GGC (glycine) in the transcribed strand of KOS to GCG (alanine) in that of ANGpath; the latter may cause



Fig. 3

Subcutaneous muscle tissue adjacent to the inoculation site on day 3 p.i. with strain ANGpath

Excessive positive fluorescence in the muscle fibers (mainly cross sections) with the antigen accumulated in the sarcoplasm in perinuclear areas and below the sarcolemma. Occasional positivity is also in elongated fibrocytes, nerve fibers and capillary walls (magn.  $\times 500$ )




Fig. 4

Subcutaneous connective tissue on day 3 p.i. with nonpathogenic recombinant ANGpath/syn<sup>KOS</sup>

Virus antigen in a few mononuclear cells (magn.  $\times 250$ )

mutation of aa 787 of the gB polypeptide chain. The KOS and ANGpath DNA sequences of the *Sst*I-*Sal*I fragment differed from that of strain 17 in 10 nucleotides. From all these nucleotide exchanges only 2 caused codon alterations. The mutation at nt 789 (54,137) of the transcribed strand changed guanine in strain 17 to adenine in strains KOS and ANGpath, altering the codon for alanine to that for valine at aa 553. The mutation of adenine to thymine at nt 1119 (54,467) changed leucine to glutamine at aa 443. The sequence in question of strain 17 differed from that of strain F in 5 nucleotides. Finally, the corresponding sequences of strains KOS and ANGpath differed from that of strain F in 8 nucleotides.

### Discussion

Based on different pathogenicity for Balb/c mice HSV strains were divided into 3 groups (Dix *et al.*, 1983). Class I strains were highly virulent after ic as well as peripheral inoculations, class II strains were virulent after ic inoculation only, while class III strains were avirulent by both

inoculation routes. Strains KOS (wild type) and ANGpath are class II, and I strains, respectively. Our data present evidence that the nonpathogenic recombinants of ANGpath could be prepared when either the whole *Bam*HI G fragment or its *Bam*HI-*Sst*I subfragment are replaced by the corresponding KOS DNA sequences.

Many structural and nonstructural genes of HSV have been with respect to pathogenicity using deletion or insertion mutants (reviewed by Rajčáni, 1992). The most thoroughly investigated gene in this respect were those coding for thymidine kinase (Ben-Hur *et al.*, 1983), the DNA polymerase components (Day *et al.*, 1987), and the immediate early trans-activation proteins ICP0, ICP4 and ICP27 (Leib *et al.*, 1989). The *Mlu*I restriction fragment 0.761–0.832 (Rosen *et al.*, 1986) and the genome region 0.82–0.832 were also found to play an important role in HSV pathogenicity. Less attention, however, has been paid to glycoproteins. As shown previously, the deletion of gE gene converted ANGpath into a class II virus nonpathogenic after peripheral inoculation (Schranz *et al.*, 1989; Rajčáni *et al.*, 1990a). This paper presents results on the role of gB mutations for pathogenicity.

The essential glycoprotein B harbors up to 18 epitopes (Pereira *et al.*, 1989) and many mutation sites (Highlander *et al.*, 1989) in its external domain, which provide important





Fig. 5

The right trigeminal ganglion on day 6 p.i. with strain ANGpath. Excessive positivity is in pseudounipolar neurons, perineural satellites and Schwann cells (magn.  $\times 500$ ).




Fig. 6

The right trigeminal ganglion on day 6 p.i. with strain ANG. PAP staining. The same finding as in Fig. 5 (magn.  $\times 600$ ).



Fig. 7

Brain stem on day 6 p.i. with strain ANGpath. Virus antigen is present in neurons and glial cells of nucleus terminalis nervi trigemini (magn.  $\times 200$ ).

antigens including a neutralization site. As mentioned above, the  $\text{syn}^3$  locus is located in the cytoplasmic part of the polypeptide chain confirming that gB is involved in virus penetration and membrane fusion (de Luca *et al.*, 1982; Bzik *et al.*, 1984). The latter function has been repeatedly associated with pathogenicity, though loci coding for virulence-related functions and giant cell formation are not identical. The *EcoRI* F fragment (0.32 – 0.42) which includes the gB gene was designated inv-II, was associated with neuroinvasivity (Goodman *et al.*, 1989). In our hands ANGpath, a syncytial strain, was virulent in comparison to KOS nonsyn. In addition, the recombinant ANGpath/B6<sup>KOS</sup> containing the original *BamHI*-*SstI* fragment of ANGpath was as virulent as the ANGpath strain. The recombinants nonpathogenic for mice had either the whole gB<sup>KOS</sup> gene or the *BamHI*-*SstI* subfragment of KOS DNA. Thus, at least one of several virulence-related loci resides in the cytoplasmic domain of gB. Lange-Bay (1990) has shown by sequencing of the 270 nt long *BamHI*-*SstI* subfragment of ANGpath DNA that it differs from the same sequence of KOS DNA in 5 nucleotides, from which the change of thymidine (in the coding sequence of KOS) to cytosine (in the coding sequence of ANGpath) at nt 53,230 of the UL segment (McGeoch *et al.*, 1988) alters the codon



for valine (KOS) to that for alanine (ANGpath) at aa 854 of the gB polypeptide chain. This mutation is close to that reported aa 857 in tsB5 (Bzik *et al.*, 1984).

Because the recombinant nonpathogenic for mice ANGpath/syn<sup>+KOS</sup> was still pathogenic for rabbits, and because other preliminary results indicated that the B6 region itself was not related to virulence (Kúdelová *et al.*, 1991) we have further sequenced the *Sst*I-*Sal*I subfragment of ANGpath DNA coding for the region close to the transmembraneous domain of the gB molecule. In comparison to KOS DNA we found an additional mutation at aa 515 close to the entry locus (aa 525) in the surface domain (Pereira *et al.*, 1989). This finding is in accord with observations on dissociation between syncytial phenotype and virulence (Wheeler, 1964; Yamada *et*

*al.*, 1986) and indicates that gB has at least 2 infectivity-related loci, one for penetration and another for membrane fusion.

Highly pathogenic strains such as SC16 and ANGpath showed a combined neural spread because they replicate in Schwann cells and endoneural cells of peripheral nerves (Rajčáni and Conen, 1972; Rajčáni *et al.*, 1990a), while the nonpathogenic recombinants can reach the first neuron in regional sensory ganglion by axonal transport only without subsequent multiplication in ganglion cells. At early postinfection intervals pathogenic viruses spread by haematogenous route invading the endothelium cells of postcapillary venules at the inoculation site. No involvement of remote CNS structures such as brain cortex and hippocampus was seen after entering the brain along the trigeminal nerve. The

	1	14				59
KOS	CCTTGGTGGT	TAGAGGGTAC	AGGGCCTTCA	TGGGGTTGCT	CTGCAGCCGC	ATGACGTAAC
F		C				G
17		C				G
ANGpath		A				A
	61	78	86/7			
KOS	GAAAGGCGAA	GAAGGCCCGCC	GCCAGGCCGG	CCAGGACCAA	CAGACCCACG	GCCAGCGCCC
F		A	GC			
17		G	GC			
ANGpath		G	CG			
	121					
	CAAAGGGGTT	GGACATGAAG	GAGGACACGC	CCGACACGGC	CGATACCACG	CCGCCCACGA
	181					
	TGCCCCATCAC	CACCTTGCCG	ACCGCGCGCC	CCAGGTCGCC	CATCCCCCTCG	AAGAACGCGC
	241	251				
KOS	CCAGGCCCGC	GAACATGGCG	GCGTTGGCGT	CGGCGTGGAT	GACCGTGTCTG	ATGTCGGCGA
F		G				
17		A				
ANGpath		G				
	301					
	AGCGCAGGTC	GTGCAGCTGG	TTGCGGCGCT	GGACCTCCGT	GTAGTCCAGC	AGGCCGCTGT
	361					
	CCTTGATCTC	GTGGCGGGTG	TACACCTCCA	GGGGGACAAA	CTCGTGATCC	TCCAGCATGG
	421					
	TGATGTTGAG	GTCGATGAAG	GTGCTGACGG	TGGTGATGTC	GGCGCGGCTC	AGCTGGTGGG
	481			520		
KOS	AGTACGCGTA	CTCCTCGAAG	TACACGTAGC	CCCCACCGAA	GGTGAAGTAG	CGCCGGTGTC
F				G		
17				A		
ANGpath				A		
	541					
	CCACGGTGCA	CGGCTCGATC	GCATCGCGCG	TCAGCCGCAG	CTCGTTGTTC	TCCCCAGCT
	601					
	GCCCCTCGAC	CAACGGGCCC	TGGTCTTCGT	ACCGAAAGCT	GACCAGGGGG	CGGCTGTAGC
	661					
	AGGCCCCGGG	CCGCGAGCTG	ATGCGCATCG	AGTTTTGGAC	GATCACGTTG	TCCGCGGCGA
	721					
	CCGGCACGCA	CGTGGAGACG	GCCATCACGT	CGCCGAGCAT	CCGCGCGCTC	ACCCGCCGGC

Fig. 8

Sequence of the *Sst*I-*Sal*I subfragment of gB gene strain ANGpath DNA nt 53,348 (numbered 1) – 54,826 (numbered 1478) as compared to that of strains KOS, F and 17

The crucial mutation by which KOS DNA differs from ANGpath DNA is at nt 903.

	781	789					
KOS	CCACGGTGAC	CGAGGCGATG	GCGTTGGGGT	TCAGCTTGCG	GGCCTCGTTC	CACAGGGTCA	
F		G					
17		G					
ANGpath		A					
	841	854					
KOS	GCTCGTGATT	CTGTAGCTCG	CACCACGCGA	TGGCAACGCG	GCCCAACATA	TCGTTGACAT	
F		C					
17		C					
ANGpath		T					
	901	3		934			
KOS	GGCGCTGTAT	GTGGTTGTAC	GTAAACTGCA	GCCGGGCGAA	CTCGATGGAG	GAGGTGGTCT	
F		C		G			
17		C		T			
ANGpath		T		G			
	961						
	TGATGCGCTC	CACGGACGCG	TTGGCGCTGG	CCCCGGGCGG	CGGGGGCGTG	GGGTTTGGGG	
	1021	1037					
KOS	GCTTGCGGCT	CTGCTCTCGG	AGGTGTTCCC	GCACGTACAG	CTCCGCGAGC	GTGTTGCTGA	
F		T					
17		G					
ANGpath		T					
	1081			1119			
KOS	GAAGGGGCTG	GTACGCGATC	AGAAAGCCCC	CATTGGCCTG	GTAGTACTGC	GGCTGGCCCA	
F				A			
17				A			
ANGpath				T			
	1141						
	CCTTGATGTG	CGTCGCGTTG	TACCTGCGGG	CGAAGATGCG	GTCCATGGCG	TCGCGGGCGT	
	1201						
	CCTTGCCGAT	GCAGTCCCCC	AGGTCCACGC	GCGAGAGCGG	GTACTIONGTC	AGGTTGGTGG	
	1261	1286					
KOS	TGAAGGTGGT	GGATATGGCG	TCGGAGGAGA	ATCGGAAGGA	GCCGCCGTAC	TCGGAGCGCA	
F			G				
17			A				
ANGpath			G				
	1321	1334					
KOS	GCATCTCGTC	CACTTCCTGC	CACTTGGTCA	TGGTGCAGAC	CGACGGGCGC	TTTGGCACCC	
F		C					
17		C					
ANGpath		T					
	1381						
	AGTCCCAGGC	CACGGTGAAC	TTGGGGGTGCG	TGAGCAGGTT	CCGGGTGGTC	GGCGCCGTGG	
	1441						
	CCCGGGCCTT	GGTGGTGAGG	TCGCGCGCGT	AGAAGCCG			

Fig. 8 (continued)

latter rather occurs after intranasal inoculation (Webb *et al.*, 1989). Because HSV is known to spread by transneuronal transport (Norgen and Lehman, 1989) and its distribution within CNS depends on the inoculation site, we assume that haematogenous dissemination may not be essential for invasion of nervous system.

The gB seems to contribute to virulence, acting in accord with other genes such as the DNA polymerase gene com-

plex, thymidine kinase and the immediate early transactivation proteins. To obtain further evidence for this hypothesis, the *Bam*HI G fragment of ANGpath DNA was recombined into KOS DNA. However, the recombinant KOS/gB<sup>path</sup> contained only the ANGpath sequence corresponding to the *Bam*HI-*Sst*I and *Sst*I-*Sal*I subfragments and was of B6<sup>+</sup> phenotype. This latter recombinant was only moderately pathogenic showing properties intermediate between strain

KOS and ANGpath (data not shown). This results is not contradictory to our hypothesis. It shows that gB is one of many genes possibly involved in HSV-1 virulence.

**Acknowledgements.** The authors thank Dr.K.W.Knopf from DKFZ, Heidelberg for helpful discussions and for his contribution to DNA sequence alignments. They also feel deeply indebted Prof. Dr.E.Weber from the Biostatistics Department of DKFZ, Heidelberg, for his cooperation at statistical analysis. A part of this work was supported by the grant of Slovak Academy of Sciences No. 2/999512/92.

## References

- Ben-Hur, T., Hadar, J., Shtram, Y., Gilden, D.H., and Becker, Y. (1983): Neurovirulence of herpes simplex virus type 1 depends age of mice and thymidine kinase expression. *Arch. Virol.* **78**, 303–308.
- Bzik, D.J., Fox, B.A., DeLuca, N.A., and Person, S. (1984): Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: mutations affecting rate of virus entry and cell fusion. *Virology* **137**, 185–190.
- Cai, W., Person, S., Warner, S.C., Zhou, J., and DeLuca, N.A. (1987): Linker-insertion nonsense and restriction site deletion mutations of the gB glycoprotein gene of herpes simplex virus type 1. *J. Virol.* **61**, 714–21.
- Culling, C.F.A., Allison, R.T., and W.T. Barr (1985): *Cellular Pathology Technique*, fourth edition, Butterworths, London, pp. 366–376.
- Day, S.P., Lausch, R.N., and Oakes, J.E. (1987): Nucleotide sequences important in DNA replication are responsible for differences in the capacity of two herpes simplex virus strains to spread from cornea to central nervous system. *Curr. Eye Res.* **6**, 19–26.
- DeLuca, N.A., Bzik, D.J., Bond, V.C., Person, S., and Snipes, W. (1982): Nucleotide sequences of herpes simplex virus type 1 (HSV-1) affecting virus entry, cell fusion and production of glycoprotein B (VP7). *Virology* **122**, 411–423.
- Dix, R.D., McKendall, R.R., and Baringer, J.R. (1983): Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral and intracerebral inoculation of Balb/c mice. *Infect. Immun.* **40**, 103–112.
- Goodman, J.L., Cook, M.L., Sedarati, F., Iyumi, K., and Stevens, J.G. (1989): Identification, transfer, and characterization of cloned herpes simplex virus invasiveness regions. *J. Virol.* **63**, 1153–1161.
- Graham, G.L., Veldhuisen, G., and Wilkie, N.M. (1973): Infectious herpes-virus DNA. *Nature (New Biol.)* **245**, 265–266.
- Haffey, M.L., and Spear, P.G. (1980): Alterations in glycoprotein gB specified by mutants and their revertants in herpes simplex virus type 1 and relationship to other mutant phenotypes. *J. Virol.* **35**, 114–128.
- Highlander, S.L., Dorney, D.J., Gage, P.J., Holland, T.C., Cai, W., Person, S., Levine, M., and Glorioso, J.C. (1989): Identification of mutations in herpes simplex virus type 1 glycoprotein B which alter antigenic structure and function in virus penetration. *J. Virol.* **63**, 730–738.
- Holland, T.C., Sandri-Goldin, R.M., Holland, L.E., Marlin, S.D., Levine, M., and Glorioso, J.C. (1983): Physical mapping of the mutation in an antigenic variant of herpes simplex virus type 1 by use of an immunoreactive assay. *J. Virol.* **46**, 649–653.
- Kaerner, H.C., Schröder, C.H., Ott-Hartmann, A., Kümel, G., and Kirchner, H. (1983): Genetic variability of herpes simplex virus: development of a pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 strain in mouse brain. *J. Virol.* **46**, 83–93.
- Kümel, G., Schröder, C.H., and Kaerner, H.C. (1986): Neurovirulence and latency in inbred mice of two HSV-1 intrastrain variants of divergent pathogenicity. *Med. Microbiol. Immunol.* **174**, 313–324.
- Kúdelová, M., Košťál, M., Červenáková, L., Rajčáni, J., and Kaerner, H.C. (1991): Pathogenicity and latency competence for rabbits of the herpes simplex virus type 1 ANGpath gC and gE defective mutants. *Acta virol.* **35**, 438–449.
- Lange-Bay, K. (1990): Identifizierung des Glykoprotein B als ein Viraler Faktor der Neuropathogenität von HSV-1 anhand Rekombinationsexperimenten mit definierten HSV-1 Fragmenten. Fakultät für Biologie der Ruprecht-Karls Universität Heidelberg, Diplomarbeit.
- Leib, D.A., Coen, D.M., Bogard, C.L., Hicks, K.A., Yager, D.R., Knipe, D.M., Tyler, K.L. and Schaffer, P.A. (1989): Immediate early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. *J. Virol.* **63**, 759–768.
- McGeoch, D.J., Dalrymple, M.A., Davison, A.J., Dolan, A., Frame, M.C., McNab, D., Perry, L.J., Scott, J.E., and Taylor, P. (1988): The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. *J. gen. Virol.* **69**, 1531–1574.
- Norgen, R.B., and Lehmen, M.N. (1989): Retrograde transneuronal transport of herpes simplex virus in the retina after injection in the superior colliculus, hypothalamus and optic chiasm. *Brain Res.* **479**, 374–378.
- Pellet, P.E., Kousoulas, K.G., Pereira, L., and Roizman, B. (1985): Anatomy of the herpes simplex virus strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistant mutants. *J. Virol.* **53**, 243–253.
- Pereira, L., Dondero, D. and Roizman, B. (1982): Herpes simplex virus glycoprotein gA/B: evidence that the infected Vero cell products comap and arise by proteolysis. *J. Virol.* **44**, 88–97.
- Pereira, L., Ali, M., Kousoulas, K., Huo, B., and Banks, T. (1989): Domain structure of herpes simplex virus 1 glycoprotein B: neutralizing epitopes map in regions of continuous and discontinuous residues. *Virology* **172**, 11–24.
- Rajčáni, J., and Conen, P.E. (1972): Observations on neural spread of herpes simplex virus in suckling mice. An electron microscopic study. *Acta virol.* **16**, 31–40.
- Rajčáni, J., Herget, U., and Kaerner, H.C. (1990a): Spread of herpes simplex virus strains SC16, ANG, ANGpath and its glyC and glyE minus mutants in DBA-2 mice. *Acta virol.* **34**, 305–320.
- Rajčáni, J., Herget, U., Košťál, M., and Kaerner, H.C. (1990b): Latency competence of herpes simplex virus strains ANG, ANGpath and its gC and gE minus mutants. *Acta virol.* **34**, 477–486.
- Rajčáni, J. (1982): DNA regions and genes determining the virulence of herpes simplex virus. *Acta virol.* **36**, 208–222.
- Rosen, A., Ernst, F., Koch, H.G., Gelderblom, H., Darai, G., Hadar, J., Tabor, E., Ben-Hur, T., and Becker, Y. (1986): Replacement of the deletion in the genome (0.762–0.789) of avirulent HSV-1 HFEM using cloned Mlu I DNA fragment (0.762–0.796 MU) of virulent HSV-1 F leads to generation of virulent intratypic recombinant. *Virus Res.* **5**, 157–175.
- Ruyechan, T.W., Morse, L.S., Knipe, D.M., and Roizman, B. (1979): Molecular genetics of herpes simplex virus. II. Mapping of the major viral glycoproteins and the genetic loci specifying the social behaviour of infected cells. *J. Virol.* **29**, 677–697.

- Schranz, P., Neidhardt, H., Schroder, C.H., and Kaerner, H.C. (1989): A viable HSV-1 mutant deleted in two nonessential major glycoproteins. *Virology* **170**, 273–276.
- Schröder, C.H., and Kümel, G. (1986): Virulent and avirulent HSV-1 : pathogenesis and molecular biology. In C.Lopez, B.Roizman (Eds): *Human Herpesvirus Infections*. Raven Press, New York, pp. 13–23.
- Sears, A.E., Meigner, B., and Roizman, B. (1985): Establishment of latency in mice by herpes simplex virus 1 recombinants that carry insertions affecting regulation of the thymidine kinase gene. *J. Virol.* **55**, 410–416.
- Spear, P.G. (1985): Glycoproteins specified by herpes simplex viruses. In B.Roizman (Ed.) : *The Herpesviruses*. Vol 3, Plenum Med. Press, New York, pp.315–356.
- Thompson, R.L. Rogers, S.K., and Zerhusen, M.A. (1989): Herpes simplex virus neurovirulence and productive infection of neural cells is associated with a function which maps between 0.82–0.832 map units of the HSV genome. *Virology* **172**, 435–450.
- Webb, S.J., Eglin, R.P., Reading, M., and Esiri, M.M. (1989): Experimental murine herpesvirus encephalitis: immunohistochemical detection of virus antigen. *Neuropathol. Appl. Neurobiol.* **15**, 165–174.
- Weise, K., Kaerner, H.C., Glorioso, J., and Schröder, C.H. (1987): Replacement of glycoprotein B gene sequences in herpes simplex virus type 1 strain ANG by corresponding sequences of the strain KOS causes changes of the plaque morphology and neuropathogenicity. *J. gen. Virol.* **68**, 1909–1919.
- Wheeler, Jr., C.E. (1964) : Biological comparison of a syncytial and a small giant cell-forming strain of herpes simplex. *J.Immunol.* **93**, 749–756.
- Yamada, M., Uno, F., and Nii, S. (1986): *In vitro* cytopathology and pathogenicity to inbred mice shown by five variants of a laboratory strain of type 1 herpes simplex virus. *Arch. Virol.* **90**, 183–196.